tak-988
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 20, 2019 (NCT04082481)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Orexin receptor 2AGONIST
HCRTR2 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05131971 | Phase 1 | Nov 1, 2021 | GlaxoSmithKline |
| NCT04082481 | Phase 1 | Sep 20, 2019 | Takeda |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2021 |
| Takeda | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1